Followers | 504 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Tuesday, April 14, 2015 11:33:53 AM
macd crossup
Sage Therapeutics, Inc.
215 First Street
Cambridge, MA 02142
United States
Phone: 617-299-8380
Fax: 617-299-8379
Website: http://www.sagerx.com
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its pipeline also includes second-generation molecules, such as SAGE-217, an oral therapy for orphan genetic epilepsies; and SAGE-689, an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.
Recent SAGE News
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit - SAGE • PR Newswire (US) • 09/19/2024 09:45:00 AM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 09/17/2024 10:33:39 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGE • PR Newswire (US) • 09/16/2024 09:45:00 AM
- Sage Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE • PR Newswire (US) • 09/12/2024 09:45:00 AM
- Edelson Lechtzin LLP Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 09/05/2024 08:03:00 PM
- Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE • PR Newswire (US) • 09/05/2024 12:30:00 PM
- Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE • PR Newswire (US) • 08/08/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:05:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/07/2024 08:04:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:10:32 PM
- Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 07/31/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 10:39:54 AM
- Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor • Business Wire • 07/24/2024 10:30:00 AM
- Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 • Business Wire • 07/17/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:57:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 08:57:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:16:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 10:45:00 AM
- Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease • Business Wire • 06/11/2024 10:30:00 AM
- Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/05/2024 10:30:00 AM
- Sage Therapeutics to Participate in Upcoming May Investor Conferences • Business Wire • 05/07/2024 10:30:00 AM
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress • Business Wire • 04/25/2024 10:30:00 AM
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease • Business Wire • 04/17/2024 10:30:00 AM
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 • Business Wire • 04/11/2024 10:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM